Evaluating hepatitis C treatment during pregnancy
Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy
This study tests how well a new hepatitis C treatment works for pregnant adults with a history of drug use and looks at their experience during the treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 2 sites (St Louis, Missouri and 1 other locations) |
| Trial ID | NCT06367465 on ClinicalTrials.gov |
What this trial studies
This study focuses on pregnant adults over 18 years old who have hepatitis C and a history of drug use. Participants will receive treatment with glecaprevir-pibrentasvir and will attend four in-person visits to assess treatment adherence and patient experience. The study aims to evaluate how well patients complete their treatment and their overall experience with the therapy during pregnancy. Standard care labs will be conducted throughout the study to monitor health outcomes.
Who should consider this trial
Good fit: Ideal candidates are pregnant women over 18 with a diagnosis of hepatitis C and a history of past or current drug use.
Not a fit: Patients who are not pregnant or do not have hepatitis C will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment adherence and outcomes for pregnant women with hepatitis C, ultimately benefiting both mothers and their infants.
How similar studies have performed: While there is limited data on this specific approach, similar studies have shown promise in treating hepatitis C in vulnerable populations, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use. Exclusion Criteria: \-
Where this trial is running
St Louis, Missouri and 1 other locations
- Barnes Jewish Hospital — St Louis, Missouri, United States (Recruiting)
- Washington Univeristy — St Louis, Missouri, United States (Recruiting)
Study contacts
- Study coordinator: Tracey Bach, MBA
- Email: habrockt@wustl.edu
- Phone: 314-273-6075
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.